A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years.
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2017
At a glance
- Drugs TAK 003 (Primary) ; TAK 003 (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Takeda
- 07 Sep 2016 According to a media release, interim results of this trial were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting in October 2015.
- 19 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Sep 2015 Results from phase Ib study published in the Vaccine.